Free Trial
NASDAQ:BIVI

BioVie Q3 2025 Earnings Report

BioVie logo
$1.07 +0.06 (+5.94%)
Closing price 04:00 PM Eastern
Extended Trading
$1.04 -0.03 (-3.18%)
As of 06:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioVie EPS Results

Actual EPS
-$0.15
Consensus EPS
-$0.32
Beat/Miss
Beat by +$0.17
One Year Ago EPS
N/A

BioVie Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

BioVie Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Sunday, May 11, 2025
Conference Call Time
6:00PM ET

Upcoming Earnings

BioVie's Q4 2025 earnings is scheduled for Thursday, August 21, 2025

Earnings Documents

BioVie Earnings Headlines

BioVie Inc Ordinary Shares - Class A
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
BioVie initiates SUNRISE-PD trial assessing Bezisterim
See More BioVie Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioVie? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioVie and other key companies, straight to your email.

About BioVie

BioVie (NASDAQ:BIVI), a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

View BioVie Profile

More Earnings Resources from MarketBeat